Dr. Oskar Hansson gained his PhD in neurobiology in 2001 and his M.D. in 2005. He became senior consultant in neurology in 2012 at Skåne University Hospital, Sweden, and full professor of neurology in 2017 at Lund University, Sweden. Oskar Hansson has performed internationally recognized clinical and translational research focusing on the earliest phases of Alzheimer's and Parkinson’s diseases. His landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2006) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer's disease in Sweden and internationally. His work on biomarkers has led to over 300 original peer-reviewed publications. Ten years ago, he started the prospective and longitudinal Swedish BioFINDER study (www.biofinder.se), where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders. Recently, the BioFINDER team has shown that tau-PET can differentiate Alzheimer’s from other neurodegenerative diseases (Ossenkoppele et al, JAMA, 2018), and that plasma P-tau is a novel promising blood-based biomarker for early detection of Alzheimer’s disease (Janelidze et al, Nature Medicine, 2020; Palmqvist et al, JAMA, 2020). Besides being responsible for the outpatient ward of the Memory Clinic at Skåne University Hospital, he is also in leading positions of several research networks and he is co-director of the strategic research area of neuroscience at Lund University.